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The Purines 2010 International Meeting belonging to the
well-known series of meetings started back in the 1980s of
the last century took place between May 30 and June 2,
2010, in Tarragona (Spain), a pleasant and ancient town,
located on the eastern Spanish Golden Coast (Costa
Dorada), less than 100 km south of Barcelona. Throughout
the meeting, the climate was pleasant and ideal, with the
moderately warm temperatures that characterize the spring
and summer seasons in this town. Participants (more than
400 scientists coming from many European and overseas
countries like Australia, Brazil, Canada, Japan, and USA)
enjoyed both Tarragona’s picturesque scenery of the Roman
ruins and monuments and the tasty food offered at the
Congress site or at local restaurants.
The scientific program, arranged with the support of an
International Board formed by the most eminent scientists
in the field of Purines, was very efficiently managed by the
local Organizing Committee, that included, for the most
part, Spanish researchers, but also scientists from UK
(Geoffrey Burnstock), Portugal (Rodrigo Cunha, Alex
Ribeiro, and Ana Sebastiao), and Italy (Maria Abbracchio
and Piero Borea). The program was very busy and included
six plenary lectures and 18 symposia. The organizers left a
wide space to the presentation of posters (more than 260 on
21 different topics) that were exhibited throughout the
meeting. The presence of poster presenters was required
every day in the first part of the morning, a notable change
in this series of meetings that was appreciated and
considered highly valuable by all participants. Noteworthy,
the Organizing Committee selected 45 posters for brief oral
communications to be given in three parallel sessions in the
afternoon of each day at the end of the symposia sessions.
As a tradition, the opening lecture was delivered by
Geoffrey Burnstock (University College, London, UK),
recognized all over the world as the pioneer who, more than
four decades ago, proposed the existence of purinergic
transmission and whose illuminated vision and passionate
dedication have guided hundreds of scientists over the
years. Geoff gave a very detailed and updated overview of
the localization and activity of purinergic receptors in
different cells and tissues, with particular emphasis on the
role played by purinergic signaling in central nervous system
(CNS) disorders, pain, and cancer. In the following days,
plenary lectures were given by several outstanding scien-
tists. Holger Eltzschig (University of Colorado, USA)
highlighted a novel protective role played by adenosine in
cardiac adaptation during ischemia, based on the stabiliza-
tion of the circadian gene period2 (Per2). Francesco Di
Virgilio (University of Ferrara, Italy) superbly reviewed the
history of P2X7 receptors that do not only act as mediators
of cytotoxic effects but may also promote the growth of
both normal and tumoral cells, an effect that could be
exploited for innovative antitumor therapies. Pnina Fishman
(Can-Fite BioPharma, Israel) presented very exciting find-
ings on the efficacy and safety of CF101 (IB-MECA), a
selective A3 receptor agonist, in patients bearing severe
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autoimmune inflammatory diseases such as rheumatoid
arthritis, psoriasis, and dry eye syndrome. Results from
human phase II clinical trials are very promising and
support the candidature of CF101 as a new therapeutic
agent in the management of these diseases. Other prelim-
inary results presented by P. Fishman also solicit further
studies on the effects of A3 agonists in additional human
hematological diseases and malignancies. The last two
plenary lectures were given by Marçal Pastor-Anglada
(University of Barcelona, Spain) and George Gorodeski
(University of Cleveland, USA). Marçal presented data on
the role played by different nucleotide transporters belong-
ing to the concentrative and equilibrative families, which
are present in the plasma membrane of every type of cells,
to assure not only purine salvage and metabolic turnover
but also a balanced amount of extracellular purines for cell
signaling and interactions. George Gorodeski focused on
the apoptotic/cytotoxic role played by P2X7 receptors in
epithelial cells, emphasizing the possibility of exploiting
these receptors as either potential biomarkers or as targets
for innovative pharmacological treatment of epithelial
cancers.
The 18 symposia were distributed in parallel sessions,
three in the morning and three in the afternoon of each day.
Each symposium accommodated three to four speakers,
leaving ample time for discussion. In the following pages,
we summarize some of the issues and novel findings. It is
likely that our report is biased by our personal research
interests and, therefore, we apologize for not mentioning all
the important contributions presented during the symposia
because we were unable to attend all the different sessions.
In the first symposium (S1) dedicated to Medicinal
Chemistry, the synthesis and biological activity of new
ligands for purinergic receptors were reported. In detail,
Christa Muller (University of Bonn, Germany) showed a
number of derivatives from Reactive Blue 2, some of which
behave as potent antagonists of P2Y12 receptors, whereas
some others act as selective antagonists of P2X2 receptors
or of ecto-5′-nucleotidase. Sergio Castillon (University
Rovira i Virgili, Spain) analyzed the most significant
modifications introduced in the ribose or purine moieties
of the nucleoside structure that enable new compounds to
exhibit different (antiviral, antibacterial, or antimetabolic)
properties. Gloria Cristalli (University of Camerino, Italy)
showed recent findings on new P2X3 receptor ligands,
some of which behave as partial agonists and some other as
full antagonists at these receptors, thus offering novel tools
to counteract sense painful stimuli, whereas Ad IJzerman
(Leiden University, The Netherlands) described in detail the
A2AR crystal structure, which represents an indispensable
basis for new drug design.
Three symposia (S5-13-18) were devoted to purine
metabolism and turnover. One of these, chaired by Stephen
Baldwin (University of Leeds, UK), analyzed the structure
and activity of different nucleoside transporters in parasites
or bacteria, as useful models to better understand the
function of these molecules in eukaryotic cells. The second
one dealt with the activity and the significance of enzymes
hydrolyzing adenosine triphosphate (ATP) in normal (Jean
Sevigny, University of Laval, Canada) and pathological
conditions (Maria Schetinger, University of Santa Maria,
Brazil), including vascular injury and systemic inflamma-
tion (Karen Dwyer, University of Harvard, USA), as well as
urologic disorders (Paulo Correia-de-Sà, University of
Porto, Portugal). The third symposium, chaired by Carles
Solsona (University of Barcelona, Spain), focused on the
release of purines from nervous cells through specific
proteins acting as channels (connexin 32 and pannexin 1)
and highlighted the importance of adopting sophisticated
techniques to monitor extracellular nucleotide and nucleo-
side concentrations in situ. In this respect, Beata Sperlagh
and colleagues (Hungarian Academy of Sciences, Hungary)
presented data obtained with the microelectrode biosensor
technique, which allows quantification of the efflux of
neurotransmitters, including purines, with a resolution
better than conventional methods.
Symposium S6 dealt with purinergic signaling in
development and stem cell regulation. Maria Abbracchio
(University of Milan, Italy) highlighted the pivotal role of
the P2Y-like receptor GPR17 (whose ability to respond to
uracil nucleotides has been recently confirmed by another
independent group) in oligodendrocyte differentiation and
myelin formation, and proposed this receptor as a new
pharmacological target for demyelinating diseases. Doug
Fields (NIH, USA) presented new exciting evidence in
favor of non-vesicular release of ATP by axons through
specific ion channels in response to action potentials. Due
to the close anatomical and functional relationship
between neurites and oligodendrocyte precursor cells (in
the (CNS)) or Schwann cells (in the peripheral nervous
system), this form of ATP release may play a key role in
regulating neuronal myelination during development
or after injury. Herb Zimmermann (University of Frankfurt,
Germany) overviewed the role played by adenine nucleo-
tides as paracrine or autocrine signaling molecules in
promoting the proliferation, migration, and differentiation
of neural progenitors in adult brain, whereas Katya Ravid
(Boston University, USA) showed a fundamental role
played by adenosine A2BR on mesenchymal stem cell
differentiation into bone cells. Such an effect, coupled to
the ability of these receptors to suppress osteoclast-
mediated bone resorption, potentially favors fracture heal-
ing. Other two symposia concerning the involvement of
purine receptors in sensory systems also attracted great
interest. Of these, symposium S2 was devoted to different
aspects of pain sensation. Kazu Inoue (Kyushu University,
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Japan) focused on the upregulation of P2X4 receptors in
spinal microglia after nerve injury as a consequence of
interferon-γ signaling and on its contribution to neuropathic
pain. Elsa Fabbretti (University of Nova Gorica, Slovenia)
described the involvement of P2X3 receptors, which are
upregulated via calcitonin gene-related peptide in an animal
model of migraine, in inducing nerve sensitization, which,
in turn, plays a key role in chronic pain. Stefan Lechner
(Max Delbrueck Center, Germany) focused on the periph-
eral sensitization of C-fiber nociceptors induced by UTP via
P2Y2 receptors, whereas Michael Salter (Hospital for Sick
Children, Toronto, Canada) showed disinhibition of noci-
ceptive neurons caused by brain-derived neurotrophic
factor, that is, in turn, released by microglia upon P2X4
receptor stimulation. In the second symposium, contribu-
tions focused on the involvement of purine nucleotides in
the regulation of intraocular pressure via P2Y2 receptors
(Jesus Pintor, University of Madrid, Spain), hearing
sensitivity via P2X2 receptors (Gary Housley, University
of New South Wales, Australia), olfactory system via both
ionotropic and metabotropic P2 receptors (Colleen Hegg,
Michigan State University, USA), and taste, mainly via
P2X2 and P2X3 receptors (Thomas Finger, University of
Colorado, USA).
Several symposia highlighted the role played by A2AR in
brain function. One of these (S9) was dedicated to the
interactions of A2AR with other receptors activated by
neurotransmitters or purines themselves. Serge Schiffmann
(University of Bruxelles, Belgium) and Francisco Ciruela
(University of Barcelona, Spain) emphasized the relevance
of striatal post-synaptic A2A/dopaminergic D2 and of
presynaptic A2A/A1 receptor heteromerization in modulat-
ing, respectively, striatopallidal neuronal depolarization and
corticostriatal glutamatergic afferents. It was concluded that
compounds with a preferential in vivo profile as striatal pre-
or post-synaptic A2A antagonists may be of potential utility
for the therapy of dyskinetic/obsessive-compulsive disor-
ders and drug addiction or Parkinson’s disease, respectively
(Sergi Ferrè, NIH, USA). Patrizia Popoli (ISS, Rome, Italy)
highlighted the ability of A2A receptors to heterodimerize
and functionally interact with further receptors, such as
cannabinoid CB1 receptors in striatum. Symposium S15
was devoted to the interactions between A2A and growth
factor receptors, which may play a significant role in
neurodegenerative diseases (Alex Ribeiro, University of
Lisbon, Portugal and Rod Cunha, University of Coimbra,
Portugal). In this context, Cinzia Volonté (S. Lucia
Foundation, Rome, Italy) dealt with the great heterogeneity
of purinoceptors in the cell membrane and proposed the
construction of a database to group all the known types of
receptors as homo- or heteromers and develop a mathemat-
ical model for the prediction of oligomer formation. Similar
aspects were discussed in symposium S10 on “Purinergic
signaling and brain disorders,” in which Ana Sebastiao
(University of Lisbon, Portugal), Felicita Pedata (University
of Florence, Italy), and Michael Schwarzschild (Harvard
University, USA) confirmed the crucial role played by A2A
receptors in acute or chronic brain diseases, while Alexej
Verkhratsky (University of Manchester, UK) gave an
excellent account of purinergic signaling in neuroglia,
underlying its involvement in both the physiological
regulation of glial cells and in virtually every form of
neuropathology. The widespread effects induced by caf-
feine, a well-known adenosine receptor antagonist, were
reviewed in another symposium (S3) chaired by Piero
Borea and William Lovallo. It was underlined how patients
with hypertension, showing increased CNS reactivity due to
enhanced cortisol, may have exaggerated responses to
caffeine in combination with behavioral stress. On the
other hand, new data on the consolidation and retrieval of
memory by caffeine were presented, confirming its potent
positive effects on cognitive performance.
Symposium S4 was entirely devoted to show the
functional role of P2X7 receptors, either in neurons (Maria
Teresa Miras-Portugal, University of Madrid, Spain) or
astrocytes (Peter Illes, University of Leipzig, Germany)
under physiological conditions and in neuroblastoma cells,
where P2X7 stimulation affects cell differentiation (Antonio
Artalejo, University of Madrid, Spain).
The therapeutic potential of purine drugs was discussed in
symposium S7. Ken Jacobson (NIH, USA) recalled the
therapeutic effects of some A3R agonists already discussed
by Pnina Fishman in her lecture, reporting that he is
currently working on some further molecules belonging to
the same class. He also mentioned molecules acting as
agonists or antagonists of various P2 receptors, focusing on
P2Y6 receptors, whose activation may play a protective role
in peripheral (pancreatic cells) or nervous cells. Ken also
showed data obtained with a new technique able to
incorporate fluorescent or reporter groups into ligands, thus
providing new tools for receptor assay or imaging; finally, he
provided interesting examples of multivalent G protein-
coupled receptor ligand-dendrimer (GLiDe) conjugates,
which have increased potency or selectivity in comparison
to monomeric ligands. In the same symposium, Jiang-Fan
Chen (Boston University, USA) summarized the role played
by A2AR and its ligands in the cognitive impairment and
behavioral rigidity found in acute traumatic brain injury as
well as in neurodegenerative diseases; Joel Linden (Univer-
sity of Virginia, USA) emphasized how A2AR stimulation is
able to reduce pulmonary dysfunction in mice with sickle
cell disease, thus representing an alternative potential therapy
to block the activation of CD1d-restricted iNKT cells which
are recognized to act as trigger of an inflammatory cascade.
Josè Boyer (Inspire Pharmaceuticals, USA) reported encour-
aging new data on the therapeutic potential of Denufosol, a
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P2Y2 receptor agonist, administered for 24 weeks to patients
with cystic fibrosis in comparison to a placebo within a
double-blind clinical trial. Another important symposium for
therapeutic implications was that on “Purines and Cancer”
(S17), in which Jashvant Unadkat (University of Washington,
USA) showed the important role played by nucleoside
transporters in mediating the efficacy and toxicity of
nucleoside antineoplastic drugs (such as gemcitabine or
ribavirin). In the same symposium, Igor Feoktistov (Vanderbilt
University, USA) demonstrated that the overexpression of
adenosine A2B receptors in primary human tumors seems to
promote tumor neovascularization, thus representing an
important therapeutic target in cancer biology. Sally Coulthard
(Newcastle University, UK) reported that the deletion of
methyl-thioadenosine phosphorylase in cancer cells favors the
antitumoral activity of thiopurines. Finally, Misha Sitkovsky
(Northeastern University, Boston, MA, USA) provided data
obtained with Kengo Moriyama on the role of A2A and A2B
receptor interactions in generating an immunosuppressive
response in vivo. Misha’s original findings on the critical
involvement of adenosine in the protection of normal and
cancerous tissues have been recently corroborated by inde-
pendent observations that even bacteria produce adenosine to
evade immune responses. Another symposium that dealt with
the purinergic regulation of immune cells and inflammation
was symposium S11. Carmen Montesinos (University of
Valencia, Spain) showed how promotion of wound healing by
topical application of a selective adenosine A2A agonist
requires the expression of tissue plasminogen activator, via a
complex mechanism involving its main inhibitor PAI-1 and its
cell receptor annexin II. Bruce Cronstein (New York
University School of Medicine, USA) reported evidence that
both A1 and A2A receptors play a critical role in osteoclast
formation and function. In detail, he showed that an adenosine
A2A agonist inhibits wear particle-induced bone loss, suggest-
ing this receptor as a novel target for therapies designed to
treat osteoporosis and to diminish prosthesis failure. In the
same symposium, James Wiley (University of Melbourne,
Australia) showed a novel role for the P2X7 receptor in
phagocytosis. Overexpression of P2X7 in cells greatly
augmented phagocytosis of beads and bacteria in the absence
of serum. This novel phagocytic pathway also operates in
vivo, as evidenced by inhibition of the uptake of latex beads
and bacteria by peritoneal macrophages of mice by prior
injection of ATP. Finally, Didier Communi (IRIBHM, ULB,
Belgium) reported that lipopolysaccharide and ATPγS stim-
ulated bone marrow-derived dendritic cells (BMDCs) to
secrete estimated Epidermal Growth Factor Receptor (EGRF)
ligand that, in turn, stimulated proliferation of Lewis lung
carcinoma cell growth in vitro. Interestingly, also in vivo,
tumor weights were significantly increased after co-injections
of Lewis lung carcinoma cells with lipopolysaccharide and
ATPgS-treated BMDCs or their supernatants, suggesting that
ATPgS confers tumorigenic properties to human and murine
dendritic cells.
At the end of the meeting, the Springer Prizes for the
best poster and oral presentations were awarded by Geoff
Burnstock (Editor-in-Chief of Purinergic Signalling)
and Thijs van Vlijmen (Publishing Editor of Springer
Publications) to
Filipa F. Ribeiro (Portugal)—First Poster Prize
Younis Baqi (Germany)—Second Poster Prize
Miriam Peeters (Netherlands)—First Presentation Prize
Miriam León-Otegui (Spain)—Second Presentation
Prize
In conclusion, we believe that the Tarragona meeting has
represented a good example of the vitality of research and of
the recent progresses made in the field of purinergic signaling,
where some innovative therapeutic applications are finally
coming true. The time spent in Tarragona discussing and
exchanging ideas with many colleagues was really exciting.
Due to its friendly, informal, and open atmosphere, this type
of meeting is ideal to meet old friends and welcome new
scientists entering the field. For these reasons, it is our honor
and pleasure to announce to all readers, on behalf of
corresponding organizers, several future meetings in the field:
1. First Brazilian Purine Club Meeting on Purinergic
Signaling: Biological and Therapeutic Implications,
August 23–25, 2010 Águas de Lindoia, Brazil (Organiz-
ing Committee: Henning Ulrich, Robson Coutinho-Silva,
and Ana Maria Oliveira Battastini)
2. The UK Purine Club Meeting in Nottingham, Sept 17,
2010 (Organizers: Vera Ralevic and Steve Alexander)
3. ASN (American Society of Nephrology) 2010 Sympo-
sium, Denver, CO, USA, November 16–21, 2010.
Scheduled date: November 18, 2010; title: Regulation
of Renal Function by Extracellular Nucleotides
4. Auxiliary Meeting at the ASN 2010 Venue in Denver.
Scheduled date: November 17, 2010; title: Purinergic
Signaling in the Kidney: The Present and the Future.
Both meetings N.3 and N.4 have been promoted by the
US Renal Purinergic Club
5. The Fourth German–Italian Joint Meeting belonging to
the highly successful series of the Italian–German
Purine Club meetings will be organized by Christa
Muller in Bonn, in July 2011, and will be also open to
scientists coming from all countries
6. The next international meeting of the “Purines” series
(Purines 2012) will be organized by Kazu Inoue in
2012, in Japan
More details on these exciting meetings are available on
the web.
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